Microfluidic Production Chip Company Haoli Tech Completes Pre-A Financing Round with WinX Capital as Exclusive Financial Advisor

Recently,Hangzhou Milli Technology Co., Ltd. (hereinafter referred to as “Milli Tech”), a manufacturer of microfluidic production chips, announced the completion of its Pre-A financing round. The round was led by Deshi Capital, with GSR Ventures participating as a co-investor. WinX Capital served as the exclusive financial advisor and will continue to handle subsequent fundraising efforts.The proceeds from this round of financing will be primarily used to construct a production base for agarose-based beads with a capacity of tens of thousands of liters, further advance the development of products under research, deepen the company’s layout in the life sciences sector, and accelerate mass production and commercial promotion of its products.

Hangzhou Milli Technology Co., Ltd. centers on microfluidic production-grade chips to continuously expand its universal microsphere material production platform in the life sciences sector. Leveraging a highly digitalized manufacturing model, Milli successfully accommodates diverse raw materials and achieves scalable production of microspheres with varying particle sizes and functionalities. The company provides stable, high-quality products and customized solutions for multiple fields, including biopharmaceuticals, medical aesthetics ingredients, drug delivery, and in vitro diagnostics. Furthermore, the company has commenced operations at its pilot-scale production facility capable of producing finished microspheres at the thousand-liter scale and has obtained ISO 9001 quality management system certification, ensuring the continuous provision of exceptional products and services to its customers.

 Milli Technology's Large-Scale Microsphere Production System

Dr. Han Linchen, Founder & CEO of Milli Technologystated: “We extend our sincere gratitude to investors including Deshi Capital, GSR Ventures, and existing shareholder Linear Capital for their strong recognition of Milli Technology’s platform and products. We also thank WinX Capital for its steadfast support and professional services in facilitating the completion of this financing round. Looking ahead, we will continue to uphold our philosophy of ‘winning through quality and establishing trust as our foundation,’ constantly enhancing product quality and service standards to provide life science customers with higher-quality, more efficient, and customized solutions.”

Mr. Guo Jia, Partner at Deshi Capitalstated: “We are greatly honored to lead the Pre-A financing round of Hangzhou Milli Technology Co., Ltd. The company has demonstrated exceptional capabilities in manufacturing microfluidic chips, and its microsphere products have received high recognition from customers. We believe that through its continued deep engagement in this field, the company will deliver higher-quality products and more excellent services to its customers.”

Dr. Wang Xiaoyan, Partner at Jinsha River United Capitalstated: “We are optimistic about Milli Technology’s leading high-throughput microsphere continuous production system, which offers higher production efficiency, superior product quality control, a smaller equipment footprint, and lower energy and raw material consumption. We are pleased to participate in this round of financing and hope that the company’s products will better serve the broad customer base in the life sciences sector.”

Duan Songwei, Head of WinX Capital’s Hangzhou Officestated: “WinX Capital is deeply honored to serve as the capital partner of Milli Technology and to continue leading its subsequent financing rounds. We sincerely appreciate the trust placed in WinX Capital by both the company and its investors. As a pioneer in universal production platforms for microsphere materials in life sciences, Milli Technology boasts industry-leading innovative platform technologies and product development capabilities. We believe that, with the strong support of its shareholders, the company will accelerate its growth trajectory and reach new heights.”

Kairos Capital is a specialized private equity investment management firm focused on the pharmaceutical and healthcare sectors. Dedicated to identifying investment opportunities in niche markets, Kairos Capital collaborates closely with entrepreneurs and founders to drive transformation in the pharmaceutical and healthcare industries.

GSR United Capital focuses on equity investments in the high-tech industry, with a particular emphasis on advanced manufacturing, next-generation information technology, industrial internet/digital enterprise services, and life sciences and biopharmaceuticals. In the life sciences sector, our investment team boasts over 13 years of professional investment experience, having previously led investments in more than 60 healthcare projects, thereby accumulating extensive industry resources.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering more than 3,000 active institutional investors and industrial groups. It has received numerous accolades, including being ranked No. 1 Financial Advisor in the Healthcare Sector for 2022 and 2023 by First New Voice; Top 2 Best Financial Advisor in the Healthcare Sector for 2021–2022 by Qimingpian & Xinsheng Chuangfu; and Annual Healthcare Financial Advisor by VCBeat’s “Future Healthcare 100” list from 2022 to 2024.